![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Expands Approval of Medtronic’s ‘Arctic Front’ Cardiac Catheters
FDA Expands Approval of Medtronic’s ‘Arctic Front’ Cardiac Catheters
![Medtronic_Logo_2018.gif](https://www.fdanews.com/ext/resources/test/Device_Images6/Medtronic_Logo_2018.gif?t=1580509804&width=430)
The FDA has expanded its approval of Medtronic’s ‘Arctic Front’ line of cardiac cryoablation catheters.
The expanded indication was supported by results from a clinical trial that showed the cryoablation procedure for preventing atrial arrhythmia recurrence had superior efficacy compared to anti-arrhythmic drug (AAD) therapy.
The Arctic Front catheters are used as an initial cardiac rhythm control strategy to treat recurrent symptomatic paroxysmal atrial fibrillation — episodes that last less than seven continuous days — instead of AAD therapy.
Upcoming Events
-
21Oct